Denali Therapeutics Company
Denali Therapeutics is dedicated to defeating neurodegenerative diseases through rigorous therapeutic discovery and development.
Investors
Industry:
Biotechnology, Genetics, Health Diagnostics, Therapeutics
Last Funding Type:
Series B
Funding Status:
IPO
Estimated Revenue:
$10M to $50M
Total Funding:
347000000
Investors Number:
8
Headquarters:
UK
Last Funding Date:
2016
Founded Date:
2015
Employee Number:
251-500